World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Giri S, Anirvan P, Angadi S, Singh A, Lavekar A. Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease. World J Gastrointest Pathophysiol 2024; 15(1): 91100 [PMID: 38682026 DOI: 10.4291/wjgp.v15.i1.91100]
URL:	https://www.wjgnet.com/1007-9327/full/v15/i1/91100.htm

(147) (155) (0) (0) (0) (9) (4438) (14)

Number	Citing Articles
1	Priyankar Dey. The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different?. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1693123
2	Rishi Chowdhary, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Megh Patel, Tanisha Sehgal, Kirti Arora, Rahul Chowdhary, Varun Mehta, Akash Batta, Omesh Goyal. Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study. Hepatology Research 2026; 56(6) doi: 10.1111/hepr.70158
3	Mohamed El-Kassas, Heba A. Othman, Mohamed Elbadry, Khalid Alswat, Yusuf Yilmaz. Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology 2025; 15(1) doi: 10.1016/j.jceh.2024.102415
4	Noha M. Gamil, Habiba A. Elsayed, Esraa T. Salah, Heba A. Mostafa, Riham A. El-Shiekh, Heba R. Ghaiad, Hebatollah E. Eitah. Decoding the mechanistic basis of liver–muscle communication in health and disease. Naunyn-Schmiedeberg's Archives of Pharmacology 2026; 399(8) doi: 10.1007/s00210-026-05015-3
5	Li-Zhan Bie, Chao Wu, Jia-Lu Wang. Dietary ω-3 polyunsaturated fatty acid intake improves skeletal muscle mass in patients with metabolic dysfunction-associated fatty liver disease: A nationwide cross-sectional study. World Journal of Hepatology 2025; 17(6): 107931 doi: 10.4254/wjh.v17.i6.107931 Abstract(264) \| Core Tip(282) \| Full Article(HTML)(1107) \| Full Article (PDF)-648K(122) \| Full Article with Cover (PDF)-881K(100) \| Full Article (XML)-103K(70) \| Audio-142K(13) \| Peer-Review Report-203K(75) \| Answering Reviewers-178K(71) \| Times Cited (1) \| Total Visits (1835) \| Open
6	Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru. Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease. Frontiers in Epidemiology 2026; 6 doi: 10.3389/fepid.2026.1779600
7	Sizhe Wan, Mingkai Li, Wanjun Li, Yuexiang Ren, Yuankai Wu, Qingtian Luo, Wei Gong. Development and validation of a multimodal model integrating gut microbiota and metabolite for identifying sarcopenia in patients with MASLD: a study from two centers in China. Nutrition Journal 2025; 24(1) doi: 10.1186/s12937-025-01198-2
8	Fan Zhang, Longgen Liu, Wenjian Li. Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States. Nutrition Journal 2025; 24(1) doi: 10.1186/s12937-025-01081-0
9	Amy R. Fumo, Simon I. Dreher, Pauline Morigny, Honglei Ji, Raul Terron Exposito, Tuna F. Samanci, Tushar More, Lara Ruoff, Joël J. Tissink, Carmen Paredes Yubero, Ana Jimena Alfaro, Christine von Toerne, Stefanie M. Hauck, Sophie H.A. Nusser, Zoltan Czigany, Kenneth A. Dyar, Stephan Herzig, Mauricio Berriel Diaz, Anja Zeigerer, Karsten Hiller, Theresa H. Wirtz, Cora Weigert, Maria Rohm. Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH. Molecular Metabolism 2026; 110 doi: 10.1016/j.molmet.2026.102391
10	Marwan S Al-Nimer. Sarcopenia and metabolic dysfunction-associated steatotic liver disease: The role of exercise-related biomarkers. World Journal of Hepatology 2025; 17(2): 101165 doi: 10.4254/wjh.v17.i2.101165 Abstract(423) \| Core Tip(465) \| Full Article(HTML)(1952) \| Full Article (PDF)-544K(165) \| Full Article with Cover (PDF)-739K(162) \| Full Article (XML)-64K(120) \| Audio-1168K(13) \| Peer-Review Report-251K(95) \| Answering Reviewers-65K(93) \| Times Cited (2) \| Total Visits (3146) \| Open
11	Gregory Livshits, Nader Tarabeih, Alexander Kalinkovich, Adel Shalata, Shai Ashkenazi. Metabolic and Inflammatory Biomarkers Predicting Sarcopenic Obesity and Cardiometabolic Risk in Arab Women: A Cross-Sectional Study. International Journal of Molecular Sciences 2025; 26(12) doi: 10.3390/ijms26125699
12	Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee. Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1633837
13	L. Yu. Ilchenko, V. A. Akhmedov, E. V. Vinnitskaya, E. I. Dedov, R. G. Myazin, I. G. Nikitin, A. S. Tikhomirova, I. E. Khoroshilov, G. V. Shavkuta, O. A. Ettinger, I. G. Adamova, L. B. Lazebnik. Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment (expert opinion). Experimental and Clinical Gastroenterology 2026; (4) doi: 10.31146/1682-8658-ecg-236-4-3-36
14	V. A. Prikhodko, S. V. Okovityi. L-Ornithine salts as somatotropic axis modulators for the correction of sarcopenia in chronic liver disease. Meditsinskiy sovet = Medical Council 2025; (8) doi: 10.21518/ms2025-223

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.